. Author manuscript; available in PMC: 2015 Nov 1.

Published in final edited form as: Clin Exp Ophthalmol. 2014 May 5;42(8):713–721. doi: 10.1111/ceo.12325

Table 1. Characteristics of clinical trial participants.

Type of OCA^† n (%)	OCA1A 12 (26.7%)	OCA1B 18 (40%)	OCA2 14 (31.1%)	HPS-1 1 (2.2%)
BCVA ^‡ mean (range)
BCVA at enrollment	20/106 (20/80-20/160)	20/85 (20/32-20/200)	20/75 (20/32-320)	20/100 20/100
BCVA at final visit	20/96 (20/63-20/160)	20/77 (20/32-20/160)	20/64 (20/32-20/250)	20/80 20/80
Best BCVA during trial	20/91 (20/63-20/160)	20/69 (20/25-20/160)	20/62 (20/32-20/250)	20/32 (20/32)
Genotype
2 mutations	11	7	7	1
1 mutation	1	10	8	0
No mutations	0	0	0	0
Age yrs (range)	19.4 (6.3-57)	8.9 (3.5-26.7)	16.3 (3.96-49.3)	13.0
Gender (% Female)	58%	50%	43%	100%

^†

Oculocutaneous albinism

^‡

Best-corrected visual acuity